← All trials
NCT00000579
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1994
- Primary completion
- —
- Completion date
- Jul 1, 2004
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Vanderbilt UniversityOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- University of British ColumbiaOverall official - principal investigator
- University of ChicagoOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Latter Day Saints HospitalOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- Louisiana State UniversityOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.